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Due to the high degree of resistance to antimicrobial gents of Gram-negative non- 
fermenters bacilli isolated from CF patients, there are limited therapeutic options 
available. 
The present study evaluates the activity of the most frequently used antibacterial 
drugs, and the effect of combination of two antibiotic against multiresistant Gram- 
negative non-fermentative rods. 
The bactericidal effect was investigated by E-test on 48 multiresistant s rains 
(16 P aeruginosa nd 32 B. cepacia-complex) isolated over a period of 3 years 
from CF patients attending two Italian CF Centers. 
Meropenem, ceftazidime, tobramycin, were the most active inhibiting 77, 75, 
and 71% of strains respectively. Seventy-three out of 342 (21%) tested combi- 
nations showed a synergistic effect being meropenem + ciprofloxacin (25%) and 
tobramycin + ceftazidime/ticarcillin (19%) the most active associations against 
P aeruginosa. Ceftazidime + tobramycin (41%) and meropenem + tobramycin 
(34%) were the most active against B. cepacia-complex. The higher percentage of
antagonistic effect was demonstrated formeropenem + cefepime/tobramycin (19%), 
ticarcillin + ciprofloxacin (19%) for P aeruginosa strains and cloramphenicol + 
cotrimoxazole (26%), meropenem + ciprofloxacin (25%), ceftazidime +tobramycin 
(22%) for B. cepacia-complex members. 
This study indicates that a choice of effective double antibiotic therapy cannot be 
made empirically for Gram-negative multiresistant infections. The addition of a 
second antibiotic was found to be potentially counterproductive, in fact 16% of 
tested associations resulted in antagonisms with loss of bactericidal effects. 
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Introduction: In CF acute respiratory exacerbations are usually treated by combi- 
nation therapy i.e. a f3-1actam in combination with an aminoglycoside with specific 
choice guided by recent anti-microbial sensitivity. In severe disease Temocillin has 
been used to treat acute exacerbations albeit there are few clinical trials to assess 
its efficacy. 
Aim: To assess if IV antibiotic therapy including Temocillin was non-inferior to 
standard combination therapy for an acute exacerbation f respiratory disease. 
Methods: A retrospective pilot study. Adult patients who had received a course of 
IV antibiotics which included Temocillin (TIV) and a further IV course (within +/ 
one year) which did not include Temocillin (NTIV) were included in this study. 
Outcome measures at start and end of each IV course were recorded [FEV1%, 
FVC%]. Analysis: Paired t tests were used to compare mean % change in lung 
function between TIV and NTIV courses. 
Results: 16 patients attending the adult CF centre between 1997 and 2005 had 
received Temocillin (9M:7F), age 26(6) years, B. cepacia (n 9), P aeruginosa 
(n 11). Baseline start of TIV: FEV1% 37(18)%, FVC 47(20)%; baseline start of 
NTIV: FEV1 39(20)%, FVC 51(23)%. There was a small difference in change in 
lung function TIV versus NTIV in FEV1 2.4% [95%CI: 4.16 to 9.03%]in FVC 
4.75% [95%CI: 3.36 to 12.86]. 
Discussion: These data suggests non-inferiority in the outcome of IV antibiotic 
therapy including Temocillin versus tandard IV antibiotic therapy. The confidence 
intervals for this difference are wide and although may be explained by the small 
sample size this finding would need to be investigated in a large prospective study. 
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Introduction: The emergence of acquired metallo-f3-1actamases (MBLs) in Pseu- 
domonas aeruginosa is a matter of major concern since MBL production confer 
high-level resistance to most anti-pseudomonal f3-1actams, including carbapenems. 
MBL-producing strains have been reported in hospital outbreaks wordlwide, but 
very rarely from cystic fibrosis (CF) patients. The scope of this work was to assess 
the prevalence and type(s) of MBLs in P aeruginosa from patients attending the 
CF Center of Florence (Italy). 
Methods: Forty-two P aeruginosa isolates from 38 out of 184 CF patients were 
selected as representatives of the most recent carbapenem-resistant isolates from that 
cohort of patients. MBL production was assayed by Etest and spectrophotometric 
assays. DNA hybridization, PCR and sequencing were used for molecular character- 
isation of MBL genes. When MBL production was detected, multiple isolates from 
the same patient collected over an extended period were retrospectively investigated. 
Results: Production of MBL activity was detected in 1 of 42 (2.3%) isolates. The 
MBL gene was identified as blavi M 1. Multiple isolates from the same patient were 
found to be VIM-l-positive during a 6-year period. 
Conclusions: Although relatively uncommon, MBL production was detected in 
P aeruginosa isolated from a CF patient over a prolonged period. The presence 
and persistence of these worrisome resistance determinants in P aeruginosa isolated 
from CF patients have important implications on surveillance protocols and clinical 
management of such pulmonary infections. 
• Monitoring of aminoglycoside serum levels in 
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Aims: Intravenous (IV) aminoglycosides are widely used in the treatment of 
pulmonary exacerbations of P aeruginosa infection in CF patients. Toxic effects 
of the drugs, in particular nephro- and ototoxicity, are reported. Our aim was to 
monitor the tobramycin (TO) serum levels in patients of the Tuscan CF Center in 
order to reduce undesirable effects of aminoglycosides. 
Methods: This was a retrospective study of patients who were under therapy with 
IV TO. Combination antibiotic therapy (IV TO and a beta-lactam) was administered 
twice daily to outpatients and three times daily in inpatients. Serum concentrations 
of TO were measured before the fifth infusion (baseline TO, v.n. <2 rag/L) and 
30 rain before the end of the fifth infusion (peak TO, v.n. <12 rag/L). 
Results: Between 1999 and 2005, 54 patients with a mean age of 26.2 years (9.8 SD) 
were evaluated. 244 IV cycles with TO were carried out and each patient was 
administered a mean of 4.5 cycles (4.1 SD). The mean TO dose (±SD) administered 
with each infusion was 177.8 (±49.3) rag. Basal TO serum concentration was 
within range in 226 (93.7%) out of 241 observations and out of range in 15 (6.3%). 
Eight (14.8%) of 54 patients had basal TO values out of range. Peak TO levels 
were in range in 166 (70%) out of 237 observations and out of range in 71 (30%). 
Peak TO values were out of range in 33 (61%) of 54 patients. 
Conclusions: Having discovered that basal TO levels were out of range, we decided 
to reduce the antibiotic dose to prevent side effects. Antibiotic serum levels out 
of range can be considered the expression of reduced drug elimination due to 
nephrotoxicity induced by preceding therapy cycles. 
